Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors

Table 2

Association between EGFR and clinicopathologic characteristics in patients with head and neck benign tumors.

Variables	Total ()	Low EGFR ()	High EGFR ()	cOR (95% CI)	value
Age
≤40	18 (34.6)	3 (15.7)	15 (45.5)	1
>40	34 (65.4)	16 (84.2)	18 (54.5)	0.23 (0.05-0.92)	0.038
Sex
Male	28 (53.8)	10 (52.6)	18 (54.4)	1
Female	24 (46.1)	9 (47.4)	15 (45.5)	0.93 (0.29-2.87)	0.894
Grade
Well	13 (25.0)	7 (37.0)	6 (18.2)	1
Moderate	29 (55.7)	10 (52.6)	19 (57.6)	2.22 (0.58-8.40)	0.242
Poor	10 (19.2)	1 (5.3)	9 (27.3)	10.50 (1.02-108.58)	0.049
Tumor site
Mandible	18 (34.6)	4 (12.1)	14 (42.4)	1
Nasal cavity	12 (23.1)	5 (26.3)	7 (21.2)	0.40 (0.08-1.97)	0.261
Nasopharynx	3 (5.8)	1 (5.2)	2 (6.0)	0.57 (0.04-8.05)	0.678
Oral cavity	19 (36.5)	9 (47.4)	10 (30.3)	0.32 (0.07-1.33)	0.116